


Drugs for HER-2-positive Breast Cancer (Milestones in Drug Therapy)



Growth factor receptors have long been known to drive malignant transformation and cancer progression. The epidermal growth factor receptor (EGFR, ErbB, HER) system is likely the best described membrane receptor tyrosine kinase family in malignant tumors. With implementation of the growth-inhibitory anti-HER-2 antibody trastuzumab (Herceptin) for the treatment of HER-2-positive advanced metastatic breast cancer, a new era has dawned in the therapy of this malignant disease.

Unfortunately, trastuzumab-sensitive cancers invariably develop resistance to the antibody after some time. Recent clinical studies have revealed that these refractory tumors are still responsive to inhibition of the HER receptor family using dual HER-1/-2 inhibitors such as lapatinib (Tykerb/Tyverb). Moreover, a multiplicity of novel, improved irreversibly acting small molecular HER tyrosine kinase inhibitors are in the pipeline of many drug developing companies and are being evaluated in the clinical setting.

FDA Approves Herceptin for the Adjuvant Treatment of HER2 6 days ago Milestones in Cancer Research and Discovery . Breast cancers that overexpress HER2 are particularly aggressive. Trastuzumab emtansine, an antibodydrug conjugate commonly abbreviated as T-DM1, metastatic breast cancer that had progressed after treatment with other HER2-targeted drugs. **Trastuzumab as Adjuvant Treatment for Early Stage HER-2-positive** a milestone in the treatment of HER-2-positive early breast cancer. Up to one fourth of women diagnosed with early breast cancer (EBC) have tumors that are Chemotherapy Protocols/therapeutic use Breast Neoplasms/drug therapy* **Role of trastuzumab emtansine in the treatment of HER2-positive** Growth factor receptors have long been known to drive malignant transformation and cancer progression. The epidermal growth factor receptor (EGFR, ErbB, **First-line therapy in HER2 positive metastatic breast cancer: is the** The drug combination could provide first long-lasting treatment for HER2-positive breast cancer patients with brain metastases. **PEGylated Protein Drugs: Basic Science and Clinical Applications - Google Books Result** the Adjuvant Treatment of HER2-Positive Node-Positive Breast Cancer Food and Drug Administration (FDA) approved Herceptin (Trastuzumab), HER2-positive breast cancer and another significant milestone in the **Buy Drugs for HER-2-positive Breast Cancer (Milestones in Drug** All the trastuzumab adjuvant trials enrolled patients with HER-2-positive (CHF), coronary artery disease, angina pectoris requiring medication, uncontrolled trastuzumab therapy in women with operable HER-2-positive breast cancer. **Drugs for HER-2-positive Breast Cancer - Google Books Result** Therapies. for. HER-2-positive. Breast. Cancer. Flavio F. Solca, Guenther R. Adolf, Hilary Jones Consequently, these pathways have been the focus of intense drug **Drugs for HER-2-positive Breast Cancer, Milestones in Drug Therapy, DOI Drugs for HER-2-positive Breast Cancer**

(Milestones in Drug Therapy) Milestones in Drug Therapy, DOI 10.1007/978-3-0346-0094-1_2,. Springer approved as first-line treatment for Her-2-positive metastatic breast cancer in. 2). The surgeon stated that there was no treatment, although cauterization with a .. Several milestones in the 90s included the emergence of taxanes as HER2-positive breast cancer after it was demonstrated that the drug **Hormone Therapy for Breast Cancer Fact Sheet - National Cancer Combining Targeted Drugs Effective for Metastatic Breast Cancer** Whether HER2-positive non-breast cancers are candidates for treatment with Ado-trastuzumab emtansine (T-DM1), is an antibody-drug conjugate, One of the milestone studies over the use of anti-HER2 antibody in the treatment of gastric **Targeting the Human Epidermal Growth Factor Receptor 2 Pathway** Combining two drugs that target the HER2 protein, trastuzumab may be a new treatment option for women with HER2-positive metastatic breast cancer. Milestones in Cancer Research & Discovery Stories of Discovery . Median progression-free survival was 18.5 months in the three-drug arm and **Drug combination drives HER2-positive breast cancer brain** Trastuzumab is the foundation of treatment of HER2-positive breast cancers, Recently, the clinicians armamentarium of US Food and Drug Administration **Targeted Therapy for Breast Cancer - American Cancer Society** Women with HER2-positive breast cancer that worsened after previous treatment, survived significantly longer, on average, with a combination **Adjuvant Trastuzumab: A Milestone in the Treatment of HER-2** An overview of current clinical trials for HER2-positive breast cancer at Dana-Farber. Locations Directions Community Outreach History & Milestones Awards & Honors breast cancer have inspired the creation of a series of novel drugs. Agents similar to the drug lapatinib (brand name Tykerb) that latches onto a **Understanding breast cancer****The long and winding road** This review discusses the treatment of metastatic HER2-positive BC and describes efficacy and About 20 % of invasive breast cancers (BC) are HER2-positive and .. of trastuzumab, pertuzumab and a chemotherapy drug (docetaxel, . represents now the milestone of first therapeutic approach in HER2 **Adjuvant trastuzumab: a milestone in the treatment of HER-2 - NCBI** Milestones in Cancer Research and Discovery HER2 targeted treatment has helped to change the prognosis for stage 1 to 3 breast cancers This led to the development of trastuzumab (Herceptin), a drug that has improved This led researchers to hypothesize that HER2-positive breast cancers could be slowed if the **Clinical trials for new HER2-positive breast cancer therapies - Dana** Annual Report to the Nation Cancer Portfolio Snapshots Milestones in Cancer . Hormone therapy is also a treatment option for ER-positive breast cancer that For example, the targeted therapy drug lapatinib (Tykerb) is approved to be to treat hormone receptorpositive, HER2-positive metastatic breast cancer in **Dual HER2 blockade in the neoadjuvant and adjuvant treatment of** Read Drugs for HER-2-positive Breast Cancer (Milestones in Drug Therapy) book reviews & author details and more at . Free delivery on qualified **Conjugate drug extends survival in patients with advanced HER2** These drugs work differently from chemotherapy drugs, which attack all cells that are Targeted therapy for HER2-positive breast cancer Trastuzumab (Herceptin): This drug is a monoclonal antibody, which is a man-made **Discovery: Linking HER2 to Breast Cancer - National Cancer Institute** Milestones. in. Drug. Therapy. The discovery of drugs is still an unpredictable von Itzstein (Editor), 2010 Drugs for HER2-positive Breast Cancer, C.C. Zielinski, **Drugs for HER-2-positive Breast Cancer Maria Sibilja Springer** Keywords: HER2, dual blockade, neoadjuvant, adjuvant, breast cancer, trastuzumab a milestone in the treatment of HER2-positive breast cancer (BC). three-drug combination of gefitinib, pertuzumab, and trastuzumab is **Whether HER2-positive non-breast cancers are candidates for** Editorial Reviews. Review. From the reviews: This book takes readers on a journey from HER-2 signalling to therapeutic use of trastuzumab in the neoadjuvant, **Drugs for HER-2-positive Breast Cancer (Milestones in Drug Therapy)** Milestones in Drug Therapy Drugs for HER-2-positive Breast Cancer Trastuzumab as Adjuvant Treatment for Early Stage HER-2-positive Breast Cancer. **Trastuzumab Emtansine for HER2-Positive Breast Cancer - National** These cancers are referred to as HER2-positive breast cancer. Antibodydrug conjugates are a new class of powerful drugs designed to .. Kumar G, Badve S. Milestones in the discovery of HER2 proto-oncogene and **Trastuzumab as Adjuvant Treatment for Early Stage HER-2-positive** Patients with metastatic, HER2-positive breast cancer who received a to treatment with the conjugate drug trastuzumab emtansine (T-DM1) to